The establishment of
precision medicine is considered particularly important in heterogeneous
autoimmune diseases (e.g.,
psoriatic arthritis,
systemic lupus erythematosus), which reveal clinical and molecular heterogeneity. The selection of optimal treatment strategies for individual patients may be more important and complex in
autoimmune diseases than in other diseases. Two factors are important in
precision medicine: patient stratification and use of targeted. When both factors work, patients are likely to have good outcomes. However, research into
precision medicine and its practice in systemic
autoimmune diseases is lacking. In contrast, the usefulness of peripheral immune cell phenotyping in the evaluation of immunological characteristics and stratification into subgroups of individual patients with systemic
autoimmune diseases such as
immunoglobulin 4-related disease,
systemic lupus erythematosus, and
anti-neutrophil cytoplasmic antibody-related
vasculitis was reported. Furthermore, the potential of
precision medicine using biological
disease-modifying antirheumatic drugs based on peripheral immune cell phenotyping was recently demonstrated for
psoriatic arthritis in the clinical setting.
Precision medicine has not yet been sufficiently investigated in real world clinical settings. However, a dawn of
precision medicine has emerged. We should shed further light on
precision medicine in PsA and other
autoimmune diseases. Here, we first review the usefulness of peripheral immune cell phenotyping in systemic
autoimmune diseases and the potential of
precision medicine in PsA based on this method.